• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2020 年 12 月 20 日至 2021 年 5 月 31 日美国 COVID-19 疫苗接种计划初始阶段的管辖范围成本。

Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program in the United States, December 20, 2020-May 31, 2021.

机构信息

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA.

出版信息

Vaccine. 2024 Oct 24;42(24):126287. doi: 10.1016/j.vaccine.2024.126287. Epub 2024 Sep 3.

DOI:10.1016/j.vaccine.2024.126287
PMID:39232401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11980439/
Abstract

This study aimed to quantify U.S. jurisdiction-level costs related to the COVID-19 Vaccination Program by estimating the per-dose-administered cost during December 20, 2020-May 31, 2021, from a combined federal and local government perspective. Costs were limited to vaccine purchase, administration (including operations and wastage), and local redistribution by jurisdictions. Data were collected through publicly available sources, published literature, and a survey of 62 jurisdictions (38 responded). A total of 284.6 million doses of COVID-19 vaccine were distributed to jurisdictions during the study period, of which 284.2 million doses were administered, and 0.4 million doses were wasted. The estimated cost per-dose-administered among the 38 jurisdictions that responded to study survey was $57.45 and imputed cost across all jurisdictions was $63.11. The findings on jurisdiction-level cost per-dose-administered and vaccination cost during the initial period of U.S. COVID-19 Vaccination Program, when demand exceeded supply, may be considered in future pandemic preparedness planning.

摘要

这项研究旨在通过从联邦和地方政府的综合角度估计 2020 年 12 月 20 日至 2021 年 5 月 31 日期间每剂管理成本,来量化与 COVID-19 疫苗接种计划相关的美国管辖级别成本。成本仅限于疫苗采购、管理(包括运营和损耗)以及管辖范围内的本地再分配。数据通过公开来源、已发表的文献以及对 62 个辖区(38 个做出回应)的调查收集。在研究期间,共向辖区分发了 2.846 亿剂 COVID-19 疫苗,其中 2.842 亿剂已接种,0.4 万剂被浪费。对参与研究调查的 38 个辖区的每剂管理成本估计为 57.45 美元,所有辖区的推算成本为 63.11 美元。在美国 COVID-19 疫苗接种计划初期,当需求超过供应时,有关每剂管理成本和疫苗接种成本的发现可在未来的大流行防范计划中加以考虑。

相似文献

1
Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program in the United States, December 20, 2020-May 31, 2021.2020 年 12 月 20 日至 2021 年 5 月 31 日美国 COVID-19 疫苗接种计划初始阶段的管辖范围成本。
Vaccine. 2024 Oct 24;42(24):126287. doi: 10.1016/j.vaccine.2024.126287. Epub 2024 Sep 3.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.南非 COVID-19 疫苗接种计划的成本效益分析。
Vaccine. 2024 Aug 13;42(20):125988. doi: 10.1016/j.vaccine.2024.05.036. Epub 2024 May 31.
4
Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.9 个美国司法管辖区中 COVID-19 大流行对常规儿童疫苗接种的影响。
Vaccine. 2024 Sep 17;42(22):125997. doi: 10.1016/j.vaccine.2024.05.045. Epub 2024 May 25.
5
SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey.基于人群的家庭调查得出的尼日利亚两个州的新冠病毒血清流行率和新冠疫苗接种覆盖率
Sci Rep. 2025 Aug 10;15(1):29272. doi: 10.1038/s41598-025-14253-z.
6
Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults.2023 - 2024年美国成年人新冠疫苗接种的成本效益
JAMA Netw Open. 2025 Aug 1;8(8):e2523688. doi: 10.1001/jamanetworkopen.2025.23688.
7
Covid-19 vaccine incentives' effectiveness and differential impact on high-risk groups: A prospective cohort study.新冠疫苗激励措施的有效性及其对高危人群的差异影响:一项前瞻性队列研究。
Vaccine. 2025 Aug 13;61:127302. doi: 10.1016/j.vaccine.2025.127302. Epub 2025 May 31.
8
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.针对 COVID-19 的一种改良信使核糖核酸-脂质纳米颗粒候选疫苗的安全性和免疫原性:一项 1 期、剂量递增研究的结果。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18.
9
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
10
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.2022 年至 2023 年秋冬期间,老年欧洲人群中的 COVID-19 疫苗有效性。
JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258.

本文引用的文献

1
U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023.美国 2020 年 12 月至 2023 年 5 月期间的 COVID-19 疫苗分发策略、系统、绩效和经验教训。
Vaccine. 2024 Sep 17;42 Suppl 3(Suppl 3):125703. doi: 10.1016/j.vaccine.2024.02.020. Epub 2024 Feb 15.
2
Assessment of the Costs of Implementing COVID-19 Vaccination Clinics in 34 Sites, United States, March 2021.美国 34 个地点实施 COVID-19 疫苗接种诊所的成本评估,2021 年 3 月。
J Public Health Manag Pract. 2022;28(6):624-630. doi: 10.1097/PHH.0000000000001561. Epub 2022 Aug 27.
3
Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis.疫苗应对 COVID-19 大流行的经济价值:美国成本效益和预算影响分析。
J Med Econ. 2021 Jan-Dec;24(1):1060-1069. doi: 10.1080/13696998.2021.1965732.
4
The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.美国假设的 COVID-19 疫苗的潜在公共卫生和经济效益:利用成本效益建模为疫苗接种优先级提供信息。
Vaccine. 2021 Feb 12;39(7):1157-1164. doi: 10.1016/j.vaccine.2020.12.078. Epub 2021 Jan 6.
5
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.免疫实践咨询委员会关于使用辉瑞-BioNTech COVID-19 疫苗的临时建议-美国,2020 年 12 月。
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. doi: 10.15585/mmwr.mm6950e2.
6
Pediatricians' Experiences With and Perceptions of the Vaccines for Children Program.儿科医生在儿童疫苗计划中的经验和看法。
Pediatrics. 2020 Mar;145(3). doi: 10.1542/peds.2019-1207. Epub 2020 Feb 21.
7
Financing of Vaccine Delivery in Primary Care Practices.初级保健实践中的疫苗接种融资。
Acad Pediatr. 2017 Sep-Oct;17(7):770-777. doi: 10.1016/j.acap.2017.06.001. Epub 2017 Jun 7.
8
Combination strategies for pandemic influenza response - a systematic review of mathematical modeling studies.大流行性流感应对的组合策略 - 数学建模研究的系统评价。
BMC Med. 2009 Dec 10;7:76. doi: 10.1186/1741-7015-7-76.